tetano
Editor, Senior Moderator
Vaccine. 2012 Sep 11. pii: S0264-410X(12)01292-3. doi: 10.1016/j.vaccine.2012.08.073. [Epub ahead of print]
Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011.
Hughes B, Hayden F, Perikov Y, Hombach J, Tam JS.
Source
The Wellcome Trust, 215 Euston Road, London, NW1 2BE, UK. Electronic address: b.hughes@wellcome.ac.uk.
Abstract
On 16-17 November 2011, the Initiative for Vaccine Research of the World Health Organization convened jointly with the Wellcome Trust the fifth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses'. The goals of the meeting were to examine new influenza vaccine research developments related to increased duration and breadth of protection, including immune responses against novel strains that may present zoonotic and pandemic threats; improved delivery and administration; and safety issues related to novel vaccine approaches. A number of investigational vaccines based on unique antigens, adjuvants, and/or modes of delivery were presented. The challenges for feasible regulatory pathways to approval of such vaccines were discussed.
Copyright ? 2012. Published by Elsevier Ltd.. All rights reserved.
PMID:
22981850
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22981850
Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011.
Hughes B, Hayden F, Perikov Y, Hombach J, Tam JS.
Source
The Wellcome Trust, 215 Euston Road, London, NW1 2BE, UK. Electronic address: b.hughes@wellcome.ac.uk.
Abstract
On 16-17 November 2011, the Initiative for Vaccine Research of the World Health Organization convened jointly with the Wellcome Trust the fifth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses'. The goals of the meeting were to examine new influenza vaccine research developments related to increased duration and breadth of protection, including immune responses against novel strains that may present zoonotic and pandemic threats; improved delivery and administration; and safety issues related to novel vaccine approaches. A number of investigational vaccines based on unique antigens, adjuvants, and/or modes of delivery were presented. The challenges for feasible regulatory pathways to approval of such vaccines were discussed.
Copyright ? 2012. Published by Elsevier Ltd.. All rights reserved.
PMID:
22981850
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22981850